Amer Mirza Appointed Chief Scientific Officer at Prolynx
Prolynx, a biotechnology firm, has appointed Amer Mirza, PhD, as Chief Scientific Officer to advance its pipeline of ultra-long-acting medicines for obesity and metabolic conditions. Mirza brings extensive drug development experience.
Prolynx, a biotechnology company focused on metabolic diseases, has appointed Amer Mirza, PhD, as its Chief Scientific Officer (CSO). This appointment is intended to drive the company's research and development efforts for its portfolio of ultra-long-acting medicines targeting obesity and related metabolic conditions.
Dr. Mirza possesses nearly 25 years of experience in drug discovery and development, with specialized expertise in metabolic diseases, translational science, and preclinical pharmacology. His career includes senior R&D and translational leadership roles at companies such as Septerna, Ascendis Pharma, Gilead Sciences, and XOMA, where he was involved in progressing drug candidates.
As CSO, Dr. Mirza will oversee the execution of R&D strategies at Prolynx. The company is developing a new generation of therapies designed for extended release, aiming for monthly or quarterly administration. This approach seeks to improve tolerability and treatment adherence for patients with chronic metabolic disorders.
Executive search firm Slone Partners facilitated the recruitment of Dr. Mirza for Prolynx. The company, backed by investors including 5AM Ventures, OrbiMed, and Monograph Capital, is based in Emeryville, California, and focuses on overcoming challenges in chronic treatment adherence for metabolic diseases.